DekaBank Deutsche Girozentrale Trims Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

DekaBank Deutsche Girozentrale cut its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.4% in the third quarter, HoldingsChannel.com reports. The firm owned 54,907 shares of the biopharmaceutical company’s stock after selling 2,546 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Halozyme Therapeutics were worth $3,101,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Whittier Trust Co. purchased a new position in Halozyme Therapeutics during the first quarter valued at $27,000. GAMMA Investing LLC grew its stake in Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 254 shares in the last quarter. International Assets Investment Management LLC purchased a new position in Halozyme Therapeutics during the second quarter valued at $33,000. Skandinaviska Enskilda Banken AB publ purchased a new position in Halozyme Therapeutics during the second quarter valued at $49,000. Finally, Fidelis Capital Partners LLC purchased a new position in Halozyme Therapeutics during the first quarter valued at $52,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $57.15 on Friday. The firm has a 50-day moving average price of $57.10 and a 200-day moving average price of $51.81. The firm has a market capitalization of $7.24 billion, a PE ratio of 21.40, a price-to-earnings-growth ratio of 0.49 and a beta of 1.27. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. Halozyme Therapeutics, Inc. has a 12-month low of $33.15 and a 12-month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.73 by $0.18. The company had revenue of $231.40 million for the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The firm’s revenue was up 4.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.68 EPS. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 3.71 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. TD Cowen increased their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $58.00 to $62.00 in a research report on Monday, October 7th. The Goldman Sachs Group increased their price objective on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.00.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $9,254,244.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total value of $532,600.00. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $9,254,244.56. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the transaction, the director now directly owns 69,874 shares in the company, valued at $4,031,729.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 89,881 shares of company stock valued at $5,169,834 in the last 90 days. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.